Universal Vision Biotechnology Co., Ltd.
3218.TWO
Taipei Exchange141.00
TWD
- -
- -
Universal Vision Biotechnology Co., Ltd.
3218.TWO
(Taipei Exchange)
Recent
price
141.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Universal Vision Biotechnology Co., Ltd. (3218.TWO) operates as a leading provider of comprehensive vision care services and products across Taiwan and mainland China, specializing in ophthalmic medical treatments, optical retail, and biotechnology solutions for eye health. Founded in 1994 by ophthalmologists Dr. Pi-Jung Lin and Dr. Shu-Fang Ou and headquartered in Taipei, Taiwan, the company publicly listed on the Taipei Exchange in 2004 and manages a network of approximately 25 affiliated eye clinics and 38 optical stores in Taiwan alongside 10 eye clinics and 10 optical stores in China, primarily concentrated in eastern regions such as Shanghai, Ningbo, Suzhou, and Hangzhou. Its core offerings encompass advanced laser vision correction procedures including VISX excimer laser refractive surgery, SMILE, SMILE PRO, and Presbyond MEL90 excimer laser for presbyopia; femtosecond laser-assisted cataract surgeries with Alcon LenSx; intraocular lens implants; myopia control programs; eye plastic and micro cosmetic surgeries; aesthetic medicine consulting; hospital management, optometric, and technical consultancy services; leasing of medical devices; medical and scientific prescription eyeglasses; sunglasses, fashionable and reading glasses, progressive lenses for presbyopia; contact lenses for myopia, hyperopia, presbyopia, and astigmatism; and nutritional supplements for eye protection such as Universal lutein products, which have received SNQ, Superior Taste Award, and Gold Award by Monde Selection certifications. The company maintains the "e-Universal" brand for licensed eye clinics and "Universal Optical" for self-owned eyewear channels, delivering one-stop vision care integrating B2B ophthalmology equipment and B2C optometry services while targeting consumers seeking lifelong eye health, beauty, and corrective solutions. Recent developments include the introduction of the SMILE PRO femtosecond laser surgery instrument ahead of the Asia Pacific region and the Presbyond MEL90 excimer laser for presbyopia; establishment of new facilities such as Hangzhou Gongshu Universal Eye Center and Myopia Control Center for Teenagers at Ningbo Universal Eye Center; acquisition of Suzhou Haiweishi Eye Clinic; expansion of the Taiwan brand network to 25 affiliated eye clinics; upgrades to AA rating in MSCI ESG evaluation, Top 5% rankings in TPEx Corporate Governance Evaluations for 2022 and 2023, and receipt of the TPEx Mid-tier Partner Award, Bronze Award in TCSA Taiwan Corporate Sustainability Awards, Golden Service Certification, and selection as a Model Business Entity for Uniform Invoice Usage; and ongoing JCI accreditations for affiliated clinics marking the fifth consecutive achievement alongside multiple SNQ recognitions for supplements and operational partnerships with hospitals like Ningbo First Hospital and Hangzhou Dian Holding Co., Ltd. via Taixue Medical Investment Management (Zhejiang) Co., Ltd.